THANK YOU FOR SUBSCRIBING
The collaboration of Sanofi with Exscientia’s artificial intelligence (AI) based platform will help in designing higher quality and better targeted medicines for patients.
FREMONT CA: To develop up to 15 small molecule candidates across cancer and immunology indications using Exscientia’s artificial intelligence based platform, Sanofi has committed possibly up to $5.2 billion to collaborate with Exscientia.
Exscientia and Sanofi have agreed to collaborate in order to identify and select target projects using Exscientia's customised medicine technology. By incorporating primary human tissue samples into early target and drug development research, the platform is intended to enable a "patient-first" approach. Exscientia believes that by sticking to this approach, its researchers will be able to incorporate patient, disease, and clinically relevant data into choices on developing new medicine candidates earlier in the drug creation process.
Exscientia will lead small molecule drug design and also optimization exercises up to development candidate recommendation while, Sanofi will be in charge of preclinical and clinical development, as well as production and marketing, in addition to target discovery.
The collaboration between Sanofi and Exscientia aims to redefine how they discover and develop innovative small molecule medications for cancer and immune-mediated disorders, stated Frank Nestle, Sanofi's global head of research and CSO. Apart from shortening drug discovery timelines, AI and machine learning can also help in designing better quality medicines for patients. Sanofi has agreed to pay Exscientia $100 million in cash up front, plus up to $5.2 billion in payments connected to achieving research, translational, clinical development, regulatory, and commercial milestones.
If Sanofi commercializes a therapeutic development through the collaboration, Exscientia will be eligible to accept tiered royalties ranging from the high single digits to the mid-teens, as well as the option for clinical co-investment to increase the royalty rate up to 21 percent on net sales of co-funded products.